![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MEDTRONIC GLUCOSE MONITORING DEVICES APPROVED FOR CHILDREN, TEENS
MEDTRONIC GLUCOSE MONITORING DEVICES APPROVED FOR CHILDREN, TEENS
The FDA has approved Medtronic's REAL-Time Continuous Glucose Monitoring devices for children and teenagers ages 7 to 17, the company announced.
The MiniMed Paradigm REAL-Time System and Guardian REAL-Time System were previously approved for adult patients but will soon be released in pediatric models.
Medtronic's REAL-Time therapy aids patients in monitoring and controlling their diabetes, reducing the duration of hypoglycemic events and lowering HbA1c levels by as much as 2 percentage points, the firm said, adding that diabetes management is especially difficult for pediatric patients.
The company currently markets the MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitoring System. The Guardian REAL-Time System, a standalone continuous glucose-monitoring device, will be available later this year.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
18Jul
-
21Oct